Nevro Corp
NYSE:NVRO
Nevro Corp
Cash from Financing Activities
Nevro Corp
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nevro Corp
NYSE:NVRO
|
Cash from Financing Activities
$49.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
45%
|
CAGR 10-Years
0%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash from Financing Activities
-$2.3B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-10%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
$5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-25%
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$7.1B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
$46.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
See Also
What is Nevro Corp's Cash from Financing Activities?
Cash from Financing Activities
49.5m
USD
Based on the financial report for Dec 31, 2023, Nevro Corp's Cash from Financing Activities amounts to 49.5m USD.
What is Nevro Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
0%
The average annual Cash from Financing Activities growth rates for Nevro Corp have been -48% over the past three years , 45% over the past five years .